what hope have we got

[Gabes-Apg]

If this is how big pharma are approaching digestion issues, i hold little hope of there being half decent doctors out there to help us
Interestingly they attribute some of the profit loss to the use of wholistic therapies.....



http://www.businesswire.com/news/home/2 ... intestinal


Ulcerative colitis, IBS and Crohn’s disease segments of gastrointestinal disorder therapeutics market exhibiting rapid growth: companiesandmarkets.com

•2017 gastrointestinal disorder therapeutics market valued at $18.3 billion
•Gastroesophageal reflux disease (GERD) is largest segment
•Global incidence of Crohn’s disease is increasing steadily

LONDON--(BUSINESS WIRE)--By 2017 the gastrointestinal disorder therapeutics market is expected to be worth $18.3 billion by 2017, according to a new report available on companiesandmarkets.com. Gastrointestinal conditions tend to be most common in the elderly, and while the ageing demographic has contributed to sector growth, the market forecast figure still represents a decline of 4.8% over the 2010-2017 reporting period; attributed to the maturing global market.

Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth

http://www.companiesandmarkets.com/Mark ... 829eddaba2

The maturing world gastrointestinal disorder market is experiencing a decline in growth as a result of patent expiries, an influx of generic alternatives and widespread use of holistic therapies.

Decline within the GERD segment is having a strong impact on the overall gastrointestinal disorder market overall, attributed in part to the patent expirations of Nexium (esomeprazole) and Aciphex (rabeprazole sodium).

A rapidly growing area within the gastrointestinal disorder market is irritable bowel syndrome, which affects between 12-20% of the global population. The condition has a substantial pipeline of new treatments, e.g., Linaclotide (linaclotide acetate) and Xifaxan (rifaximin).

Despite the permanent challenge from alternative therapies and generic drugs, pharmaceutical companies are still making R&D investments for the development of gastrointestinal disorder treatments. With over 185 treatments in the pipeline - 42% of which are still at phase II - there are still opportunities for pharmaceutical companies to gain market share in this field.

The 150 page September 2011 report examines the gastrointestinal disorder therapeutics market, including forecast data to 2017 for the following geographic regions: Europe (France, Germany, Italy, Spain and UK), Japan and the US. The report discusses the competitive landscape, growth drivers/restraints, key players and products, treatment costs, M&A activity, licensing and other market influencing factors.

Key players in the gastrointestinal disorder therapeutics market include: AstraZeneca, Abbott Laboratories, Johnson & Johnson, Salix Pharmaceuticals, Ltd., Takeda Pharmaceutical Company, Pfizer, Inc and Shire Plc. Each company is analysed at length within the gastrointestinal disorder research report.

[sarkin]

Gabes,

Glad you're doing your part to keep money out of their pockets with your affordable, non-pharma GERD management. In fact, I like to think this whole forum will be a gentle force against the upward trend of the big profits pharma anticipates in this market.

Thanks for posting this looking into the mindset...

Love,
Sara

[tex]

Gee, that downward trend in pharmaceutical profits doesn't look good at all - I sure hope none of those greedy so-and-sos go broke.

Tex